Abstract
The pharmaceutical industry still produces the vast majority of their products, from powdered ingredients, in the form of solid doses.
Despite their ubiquity, powders are difficult materials to characterise and understand, as evidenced by the frequent problems encountered during manufacture. The reason for this is their complex rheological behaviour coupled with numerous environmental variations, such as humidity. Equally, the range of processes used to manipulate powders subject them to extremes of stress from high compaction loads seen in compactors to the dispersed state seen in fluidised bed dryers.
Thus, it is evident that ensuring that the powders characteristics are compatible with the way they are to be processed is a clear prerequisite for today’s Quality by Design driven manufacturing.
Modern, computer controlled instrumental techniques, including the dynamic, bulk and shear property measurements have enabled direct measurements of a powders response to aeration, consolidation and flow rate - all at low stresses - as well as quantifying shear and bulk properties (such as density, compressibility and permeability).
In order to demonstrate how fully characterising a powder can be used in the design, operation and troubleshooting of processes, this paper will present examples of common pharmaceutical unit operations and the different powder characteristics that most influence the performance of each.
Keywords: Batch granulation, wet granulation, continuous granulation, mixing, dry powder inhalation, dynamic powder testing, quality by design.
Current Pharmaceutical Design
Title:The Application of Modern Powder Characterisation Methods in Product and Process Development of Solid Dosage Forms
Volume: 21 Issue: 40
Author(s): Tim Freeman, Katrina Brockbank and Brian Armstrong
Affiliation:
Keywords: Batch granulation, wet granulation, continuous granulation, mixing, dry powder inhalation, dynamic powder testing, quality by design.
Abstract: The pharmaceutical industry still produces the vast majority of their products, from powdered ingredients, in the form of solid doses.
Despite their ubiquity, powders are difficult materials to characterise and understand, as evidenced by the frequent problems encountered during manufacture. The reason for this is their complex rheological behaviour coupled with numerous environmental variations, such as humidity. Equally, the range of processes used to manipulate powders subject them to extremes of stress from high compaction loads seen in compactors to the dispersed state seen in fluidised bed dryers.
Thus, it is evident that ensuring that the powders characteristics are compatible with the way they are to be processed is a clear prerequisite for today’s Quality by Design driven manufacturing.
Modern, computer controlled instrumental techniques, including the dynamic, bulk and shear property measurements have enabled direct measurements of a powders response to aeration, consolidation and flow rate - all at low stresses - as well as quantifying shear and bulk properties (such as density, compressibility and permeability).
In order to demonstrate how fully characterising a powder can be used in the design, operation and troubleshooting of processes, this paper will present examples of common pharmaceutical unit operations and the different powder characteristics that most influence the performance of each.
Export Options
About this article
Cite this article as:
Freeman Tim, Brockbank Katrina and Armstrong Brian, The Application of Modern Powder Characterisation Methods in Product and Process Development of Solid Dosage Forms, Current Pharmaceutical Design 2015; 21 (40) . https://dx.doi.org/10.2174/1381612821666151008124159
DOI https://dx.doi.org/10.2174/1381612821666151008124159 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Synthesis and Cytotoxic Properties of Halogen and Aryl-/Heteroarylpiperazinyl Derivatives of Benzofurans
Anti-Cancer Agents in Medicinal Chemistry Ca<sup>2+</sup> Signalling in Endothelial Progenitor Cells: A Novel Means to Improve Cell-Based Therapy and Impair Tumour Vascularisation
Current Vascular Pharmacology Alterations of the X Chromosome in Lymphocytes of Alzheimer’s Disease Patients
Current Alzheimer Research Pharmacological Risk Factors for Delirium after Cardiac Surgery: A Review
Current Neuropharmacology Interaction of Different Proteins with GABA<sub>A</sub> Receptor and their Modulatory Effect on Inhibitory Neural Transmission Leads to Epilepsy
CNS & Neurological Disorders - Drug Targets FtsZ: A Novel Target for Tuberculosis Drug Discovery
Current Topics in Medicinal Chemistry A Simple and Precise Determination of Diltiazem Hydrochloride by Simultaneous Conductometric and Potentiometric Detection
Current Pharmaceutical Analysis Antihypertensive Therapy in Children: Differences in Medical Approach Between the United States and Europe
Current Medicinal Chemistry Screening for Silent Coronary Artery Disease in Diabetics- or Not?
Current Diabetes Reviews Herbal Medicines for Diabetes Management and its Secondary Complications
Current Diabetes Reviews Nitric Oxide Mimetic Molecules as Therapeutic Agents in Alzheimers Disease
Current Alzheimer Research Biogenic Amines (BAs) in Meat Products, Regulatory Policies, and Detection Methods
Current Nutrition & Food Science Endothelial and Cardiac Dysfunction in Inflammatory Bowel Diseases: Does Treatment Modify the Inflammatory Load on Arterial and Cardiac Structure and Function?
Current Vascular Pharmacology Meet our Editorial Board Member
Cardiovascular & Hematological Agents in Medicinal Chemistry Passage of VIP / PACAP / Secretin Family Across the Blood-Brain Barrier: Therapeutic Effects
Current Pharmaceutical Design Biphenyl Amides and Isosteres as MCH R1 Antagonists
Current Topics in Medicinal Chemistry Endocannabinoid System in Neurological Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Small Molecule Inhibitors of Peptidylprolyl cis/trans Isomerase
Current Enzyme Inhibition Role of ω3 Longchain Polyunsaturated Fatty Acids in Reducing Cardio- Metabolic Risk Factors
Endocrine, Metabolic & Immune Disorders - Drug Targets Preface:
Current Vascular Pharmacology